Market Signal Briefing

Jake Claver, CEO of Digital Ascension Group, says ultra-wealthy families are rapidly accumulating XRP, and he believes most XRP holders still don’t realize how rare their position is. In a video posted on X, Claver revealed that his firm has been in recent conversations with large family offices that are now making significant allocations into XRP. 

His comments arrive at a moment when XRP’s long-term narrative is witnessing increased interest due to ETFs, and they highlight a shift happening among investors who have always avoided cryptocurrencies altogether.

Wealthy Families Quietly Accumulating XRP
Claver explained that XRP ownership is currently extremely limited relative to the global population, noting that only around 8 million wallets exist on the XRPL. Half of those wallets contain fewer than 100 XRP, which makes existing holders far more uncommon than they may think. He contrasted this with Bitcoin’s widespread ownership, arguing that XRP is still early in its adoption curve.

He said the wealthy families showing interest are not looking for quick profits. According to him, they have already built their fortunes and instead see XRP as a form of insurance. According to his post, these families are buying crypto, not to get richer, but to protect the wealth they already have. 

He described their interest in cryptocurrencies as a hedge. These investors want something uncorrelated in their portfolios ahead of any potential shock in traditional markets.

XRPUSD currently trading at $2.02. Chart: TradingView
Claver’s $10K Price Target And The Conditions He Outlined
When asked where he sees the price of XRP going, Claver stated that he believes the cryptocurrency could be trading at $10,000 by late 2026 or early 2027. He tied this prediction to how much ecosystem infrastructure becomes active on the XRPL over the next two years. 

He said the network would need substantial institutional-grade utilities, including XRP treasury systems, Evernorth’s launch, on-chain borrowing mechanisms, and new amendments to the XRP Ledger that will bring in additional compliance layers and smart-contract features.

His projection assumes that rising network volume will require higher liquidity levels and that price stability at four- and five-figure ranges will only be achievable if the ledger is handling large-scale financial flows. He also pointed to ETFs as a major factor in shaping supply and demand, noting that as ETF adoption grows, more XRP will be locked away in long-term institutional products. 

Speaking of ETFs, Spot XRP ETFs are now approaching $1 billion in total net assets and could cross that threshold within the next few days. Since their debut, these funds have taken in about $897.35 million worth of XRP from exchanges and OTC desks, and they have yet to record a single day of outflows. 

This growing demand ties directly into a quiet change happening among institutions, a trend Ripple’s CEO Brad Garlinghouse recently highlighted. He explained that Ripple is seeing notable activity through Ripple Prime, where long-watching institutions that once stayed out due to regulatory uncertainty or simple risk aversion are finally beginning to step in. 

Featured image from Unsplash, chart from TradingView

Robert Kiyosaki urges people to brace for deepening financial turmoil by building new income streams, securing essential trade skills, and accumulating hard assets as he warns of a severe global downturn approaching 2026.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

A crypto analyst has predicted another devastating Bitcoin price crash that could see the leading cryptocurrency slide back below $85,000. With its weak performance over the past few months and price action showing signs of exhaustion, the analyst has predicted that the next major support level lies more than 33% below all-time highs. 

Analyst Breaks Down Chart Signaling Bitcoin Price Crash 
TradingView crypto expert ‘EliteGoldAnalysis’ has released a fresh chart study on Bitcoin’s next selling move, warning that the cryptocurrency’s downtrend may not be over yet. The analyst’s breakdown highlights a key support level he believes Bitcoin could crash to if its current downward momentum persists. 

EliteGoldAnalysis outlines a price structure on the chart that begins with a weak high, a technical condition that often reflects a liquidity grab before a reversal. The appearance of a weak high near the top of Bitcoin’s most recent rally indicates that buyers may have been swept out before the momentum fully shifted. This pattern is accompanied by a steadily forming lower high, hinting at a developing bearish structure. 

From his perspective, the analyst explains that a short bias becomes relevant only after a clear confirmation of a bearish trend. Based on the Bitcoin price chart, such confirmation could include a break of minor support beneath the weak high, followed by a retest of that level. EliteGoldAnalysis also noted that a bearish rejection through wick actions or a strong bearish close would strengthen the case for a temporary Bitcoin price crash. 

While the analyst’s breakdown is just an interpretation of the chart rather than a trading call, Bitcoin’s price structure still hints at a possible retracement amid strengthening sell-side pressure. 

How Low Bitcoin Price Could Decline 
In his TradingView chart, EliteGoldAnalysis outlined critical zones that could dictate Bitcoin’s next bearish moves. The first region to watch is the potential “target level” marked in the purple zone above $85,000. The analyst views this level as a demand or imbalance area. Should Bitcoin reach and hold this target, it may act as the first checkpoint before the market decides whether to correct downwards or push higher. 

Just beneath the $85,000 region lies a “strong support level” highlighted in blue at $84,000 on the chart. EliteGoldAnalysis predicts that Bitcoin could decline to as low as this $84,000 support area. The analyst suggests that this level is the final retracement target, potentially representing a significant liquidity pool that could attract buyers if the price declines. 

A decisive drop toward this level would reflect a more than 6% decline from current levels above $89,000. Such a move would also mark the completion of the downside move implied by the chart structure. Over the past 24 hours, the price of Bitcoin has fallen roughly 3%, meaning a crash to $84,000 would further prolong the ongoing downtrend.  

Featured image from Unsplash, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

2 minutes ago

Bitcoin’s liveliness indicator reached new peaks, suggesting strong demand despite lower prices and signaling the bull market cycle may not be over yet.

A technical indicator called liveliness is rising, which historically signals bull run activity and could mean that this market cycle is not over yet, say analysts.

“Liveliness continues to march higher this cycle despite lower prices, indicating a floor of demand for spot Bitcoin that is not reflected in price action,” said technical analyst “TXMC” on Sunday.

The analyst explained that the “elegant metric,” which is like the long-term moving average for onchain activity, is a running sum of all lifetime spending compared to holding activity onchain. 

“It rises when coins are net transacting and falls when they’re being held, scaling by the age of those coins,” they added.

“Liveliness usually rises in bull runs as supply changes hands at higher prices, indicating a flow of newly invested capital.”Fellow analyst James Check observed that liveliness has been range-bound since the 2017 peak, up until now.

Bitcoin liveliness has reached a new peak. Source: Glassnode
Liveliness magnitude much larger this cycleCheck compared current liveliness to the 2017 cycle, which was the first “epic parabola with widespread participation.” 

The new liveliness peaks show how extreme the return of old dormant coins is this cycle, he said, adding that the magnitude of value is now much higher.

The intriguing part is, unlike 2017, where transactions were in the hundreds to thousands of dollars changing hands, this cycle, it is in the several to tens of billions of dollars, stated Check. 

“We have seen an extraordinary volume of coin days destroyed, and I am of the view we have just watched one of the greatest capital rotations and changing of the guard in Bitcoin history.”Bitcoin price starts to consolidate Bitcoin hasn’t moved much over the past 24 hours but briefly dipped below $89,000 in early Sunday trading. It had recovered to around $89,500 at the time of writing, where it was this time yesterday.

“Anything between $86,000 and $92,000 is pretty much noise. Not much will happen for BTC,” opined analyst and MN Fund founder Michaël van de Poppe on Saturday. 

If $92,000 gets tested, “I think we’ll break it, but if not, brace yourself for a test at the low $80,000 range for some sort of double-bottom pattern,” he added. 

“I don’t think we’re far off bottoming for Bitcoin, and that should result in a strong rally at the end of the year, going into Q1.”Magazine: Indian investors look beyond Bitcoin, Japan to soften crypto tax: Asia Express

ONEOK has made several acquisitions in recent years. The deals have significantly diversified its operations and grown its earnings.

HomeStock IdeasLong IdeasConsumer 

SummaryDeckers Outdoor (DECK) is rated Strong Buy with a $117 price target, offering 23% upside and market outperformance potential.DECK trades at a 14x forward P/E, a 16% discount to peers, despite premium margins and 16 consecutive double-beat quarters.Blockbuster brands UGG and HOKA drive robust top and bottom-line growth, with gross margin at 56.2% and net margin at 19%.Low leverage, strong liquidity, and active buybacks support a shareholder-friendly capital structure and bullish long-term thesis. JHVEPhoto/iStock Editorial via Getty Images

Deckers Outdoor (DECK) is a footwear design and distribution company, operating with well-known power brands, including HOKA, UGG, Teva, and others. The stock is down by more than 50% over the past

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in DECK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MSDL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The stock has fallen from a peak back in April.

Vertex Pharmaceuticals (VRTX 0.45%) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has developed a portfolio of drugs that has transformed the way the disease is treated -- and that's made Vertex the No. 1 player in the industry.

In recent years, the biotech has expanded into other treatment areas, even scoring regulatory approval for a gene editing therapy for blood disorders and a pain management drug. All of this has made Vertex a great stock to hold over time -- for example, it's climbed more than 40% over the past three years.

If you haven't yet gotten in on this growth story or aim to add to your current position, you may be on the lookout for buying opportunities. Now, with Vertex down 10% from a peak back in April, is it time to invest? Let's find out.

Image source: Getty Images.

Vertex's key growth driver
When looking at Vertex, it's important to consider its CF business as this has been the biotech's key growth driver. Vertex has developed CFTR modulators -- their role is to correct the faulty protein made by the CFTR gene. In most cases, the protein doesn't take the right shape; in others, the protein isn't even produced. This protein is needed to usher water and chloride in and out of cells, but when it's unable to do so, thick mucus builds up -- resulting in the symptoms of CF.

What makes the problem truly complex is that more than 2,000 mutations of the gene may result in this disease. But Vertex has tackled that, and its CFTR modulators can treat almost 95% of CF patients.

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net income of $1.1 billion on a GAAP basis. And the company predicts as much as $12 billion in revenue for the full year.

Today's Change

(

-0.45

%) $

-2.05

Current Price

$

455.31

Casgevy's progress
Casgevy, the blood disorders treatment, requires time to deliver growth since the therapy involves several steps that take months to complete -- so, even though the product gained approval two years ago, we're just now starting to see the revenue potential. Vertex says Casgevy is on track to reach more than $100 million in revenue for the full year 2025 and significant growth next year.

Journavx, the non-opioid treatment for moderate-to-severe acute pain, looks promising too. Vertex said more than 300,000 prescriptions have been filled for the drug from March, when it became available, through mid-October, and the company continues to study it for additional pain indications. "We're in the early days of creating another multibillion-dollar franchise," chief operating officer Stuart Arbuckle said during the recent earnings call.

Meanwhile, Vertex's CF business continues to represent a huge growth driver for the company, with intellectual property protecting its innovations through the late part of the next decade. Vertex now is studying a candidate in phase 1/2 trials that may address the remaining 5% of CF patients who can't be helped by its current portfolio. And the company recently spoke of another candidate, VX-828, a next-generation CFTR corrector -- Vertex said it was the most efficacious candidate it's ever seen in vitro, and now it's brought the candidate into clinical studies.

Made in the U.S.A.
All of this is very positive, and another important point to keep in mind is that most of Vertex's CF manufacturing is done in the U.S., so the company isn't heavily vulnerable to any potential import tariffs.

So, what are the risks involved in investing in this player? The main risk, and this is something that applies to all biotech and pharma companies, is the possibility of disappointment or failure during clinical trials. And the other risk is the commercial performance of a particular drug once launched. Vertex must put significant investment and effort into rolling out a drug like Journavx to convince doctors and hospitals that it's the best option for their patients. This, too, is a challenge that other drugmakers face.

If you can accept those risks, though, Vertex makes a fantastic biotech stock to buy -- for its dominance in CF that should support ongoing growth as well as for its growth potential in other businesses, like pain management. And now, on the dip, trading for 24x forward earnings estimates, Vertex looks like a bargain.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Sticking with this winner should pay off for investors.

Nvidia (NVDA 0.56%) has been one of the top-performing tech stocks in recent years. The shares have increased by 22,000% over the last 10 years, 1,230% in the previous five years, and 30% in the last 12 months, outpacing the Nasdaq Composite's 20% one-year return.

While there is increasing competition in the market for artificial intelligence (AI) chips, Nvidia continues to demonstrate leadership in delivering market-beating returns for investors in this bull market.

Image source: Getty Images.

Why Nvidia remains a compelling investment
There has been considerable media attention on advances in custom AI chips, such as Google's Tensor Processing Units (TPUs), and how these might negatively impact Nvidia's sales. However, one reason Nvidia is likely to continue dominating the market for data center chips is that it provides much more than just a chip.

Today's Change

(

-0.56

%) $

-1.03

Current Price

$

182.35

Nvidia offers a full technology stack of chips, software, and networking components to build AI data centers. Nvidia's GB300 Blackwell graphics processing units (GPUs) remain the most in-demand AI chip as we enter 2026. Management stated on its recent quarterly earnings call that compute capacity in cloud data centers using Nvidia chips is fully utilized, while demand for more chips remains above expectations.

With the stock continuing to trade at a reasonable forward (one-year) price-to-earnings ratio of 24, Nvidia remains one of the best growth stocks to buy right now. Analysts expect its earnings per share to compound at an annual rate of 37% over the next several years.

John Ballard has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet and Nvidia. The Motley Fool has a disclosure policy.

December 06, 2025 5:09 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about Inspire V, a sleep apnea device, including the actual market demand for the device and whether Inspire Medical had taken the steps necessary to launch it. Defendants issued a series of materially false and misleading statements that led investors to believe that demand for Inspire V was strong and that Inspire Medical had taken the necessary steps for a successful launch. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277187

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no tr.

2025 has been a rough year for the home furnishings company. Can it recover in 2026?

RH (RH +0.70%), the high-end home furnishings company formerly known as Restoration Hardware, is no stranger to volatility.

The stock has been through several boom-and-bust cycles over the last decade, most recently struggling in the post-pandemic era as the housing market has slowed to a 30-year low, dealing a blow to much of the home improvement sector. Additionally, tariffs have been another thorn in RH's side, and as a result, the stock has had a forgettable 2025 as optimism at the end of 2024 around lower interest rates and a housing market rebound has given way to a less favorable reality.

As the chart below shows, the stock is down nearly 60% this year, with essentially all of those losses coming in the first quarter, partly in response to higher tariffs than expected under President Donald Trump.

RH data by YCharts

Despite the disappointing stock performance, RH has actually delivered solid growth so far this year with revenue up 8.4% in the second quarter, and profitability has spiked as the company controlled overhead costs while doing it.

So what's in store for RH in 2026? Let's take a look at a few key factors to watch.

Image source: RH.

All eyes on the housing market
RH has managed to deliver growth in spite of a weak housing market, but there's no question that the slowdown has weighed on the business. In fact, CEO Gary Friedman, who's never afraid to share his opinion, has been outspoken on a number of occasions, reminding investors that the company is operating in "the worst housing market in almost 50 years."

No one knows where the housing market will go in 2026, though the lack of rebound thus far seems to be telling, especially as consumers are struggling, inflation remains elevated, and home prices are out of reach for many younger buyers. However, interest rates are expected to come down in December and could fall further in 2026, which would likely bring down mortgage rates.

Still, at this point, it seems risky to bet on a housing recovery in the near term.

Today's Change

(

0.70

%) $

1.12

Current Price

$

161.06

European expansion
The biggest initiative happening inside the company right now is its push into Europe. RH has opened several galleries across the pond and has more openings planned for 2026. Additionally, it expects sales at recently opened galleries, including RH Paris, which opened its doors on Sept. 5, to ramp up next year.

Among the openings planned for 2026 are marquee markets like London and Milan, and the company expects its push into Europe and the Middle East to double the size of the business in the next five to seven years.

Other factors to watch next year include tariffs, which continue to fluctuate, though the company has made significant strides in reducing its exposure to China.

After RH's sell-off in 2025, the stock is arguably undervalued. If the company can deliver and the macroeconomic environment cooperates, the stock could see a robust recovery in 2026.

December 06, 2025 17:30 ET

 | Source:

Fulcrum Therapeutics, Inc.

― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg cohort); 7 of 12 patients in the 20 mg cohort (58%) achieved absolute HbF levels ≥20% ―

― >3.75-fold mean induction of HbF at Week 12 in the 20 mg cohort among patients who reached the Week 12 visit as of November 11, 2025 data cutoff (n=6), compared to a 2.4-fold induction at Week 12 in the 12 mg cohort ―

― Consistent early evidence of pan-cellular HbF induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ―

― Pociredir continued to be generally well-tolerated, with no treatment-related serious adverse events (SAEs) ―

― Fulcrum to host investor event at 7:00 a.m. ET December 7, 2025 ―

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported positive initial results from the ongoing 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD).

“We are highly encouraged by these initial data from the 20 mg cohort, which show clear evidence of a dose-response and build on the strong profile established with the 12 mg cohort,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer. “At just six weeks of treatment, we have observed robust and clinically meaningful increases in fetal hemoglobin with the majority of patients achieving absolute HbF levels ≥20%. These results reinforce pociredir’s potential as a best-in-class, once-daily oral HbF inducer. Importantly, pociredir continues to demonstrate a favorable safety profile with no treatment-related SAEs reported.”

“These data reinforce that induction of fetal hemoglobin remains one of the most scientifically grounded strategies for treating SCD,” said Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian & Avedisian School of Medicine. “The clear dose-response observed with the 20 mg cohort, including robust early increases in HbF and evidence suggesting pan-cellular induction, is consistent with the mechanistic understanding that higher and more uniformly expressed HbF can inhibit polymerization of sickle hemoglobin, the root cause of SCD. These results represent an important step in evaluating the therapeutic potential of pociredir.”

Trial Design and Data Cut Overview

PIONEER is a Phase 1b open-label dose-escalation clinical trial evaluating the safety and efficacy of pociredir, an oral once-daily HbF inducer, in adult patients with severe SCD. The 20 mg cohort of the Phase 1b PIONEER trial includes 12 adults with severe SCD. At the November 11, 2025 data cutoff, all 12 patients completed the Week 6 visit and are included in the Week 6 analyses. Six patients (50%) who enrolled earlier in the cohort reached the Week 12 visit at the time of data cutoff and are included in the Week 12 analyses. Week 6 results therefore reflect all 12 patients, while Week 12 results reflect the first 6 patients to complete the full treatment period. All 12 patients are expected to complete the full 12-week treatment period, and Fulcrum plans to report updated results in Q1 2026.

PIONEER Study 20 mg Dose Cohort Initial Efficacy Data

Initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial (n=12) are as follows:

Mean absolute HbF increased by 9.9% at 6 weeks of treatment with pociredir (vs. 5.6% at Week 6 and 8.6% at Week 12 in the 12 mg cohort), increasing from a baseline of 7.1% to 16.9%. As of the November 11, 2025 data cutoff, 7 of 12 patients (58%) achieved absolute HbF levels ≥20% at Week 6, and all patients demonstrated a robust HbF increase. HbF levels of 20% are associated with ~90% of patients experiencing zero VOCs per year, based on real-world data presented by Fulcrum at the 20th Annual Sickle Cell & Thalassemia Conference (ASCAT) in October 2025.A clear dose-response was observed, with a >3.75-fold mean induction of HbF at Week 12 among patients who reached the Week 12 visit as of the November 11, 2025 data cutoff (n=6), compared to a 2.4-fold mean induction at Week 12 in the 12 mg cohort. The average baseline for these six patients is 5.0% as compared to 7.1% for the full cohort. Fold induction accounts for differences in baseline HbF levels and enables a normalized comparison of dose-response.The proportion of F-cells (HbF-containing red blood cells) increased from a mean of 31% at baseline to 58% at Week 6 (n=9), indicating early progression toward pan-cellular HbF induction (evenly distributed across red blood cells). F-cells are resistant to sickling and hemolysis because of HbF-mediated inhibition of sickle hemoglobin (HbS) polymerization. Consequently, higher proportions of F-cells are associated with improved red blood cell health.Markers of hemolysis and erythropoiesis improved at Week 6: Indirect bilirubin decreased by 37% (vs. 37% at Week 12 in the 12 mg cohort)Lactate dehydrogenase (LDH) decreased by 37% (vs. 28% at Week 12 in the 12 mg cohort)Red cell distribution width decreased by 22% (vs. 27% at Week 12 in the 12 mg cohort)Reticulocyte counts decreased by 33% (vs. 31% at Week 12 in the 12 mg cohort), indicating healthier bone marrow function Mean hemoglobin increased by 0.8 g/dL at Week 6 (vs. 0.9 g/dL at Week 12 in the 12 mg cohort), increasing from a baseline of 7.3 g/dL to 8.1 g/dL. Combined with reductions in reticulocyte counts, these findings indicate decreased red blood cell destruction and improvements in anemia.A trend of reduced VOC frequency was observed relative to patients’ documented VOC frequency during the 6–12 months prior to enrollment. As of November 11, 2025 data cut off, eight of 12 patients (67%) reported no VOCs during the treatment period. Pociredir Safety Update

As of the November 11, 2025 data cutoff, pociredir has been dosed in 148 adults, including 89 subjects in multiple dose cohorts up to 12 weeks. 103 healthy subjects, including 44 who received pociredir for 10 to 14 days treatment duration45 SCD patients who received pociredir for up to 12 weeks treatment duration The safety profile observed in the 20 mg dose cohort as of the November 11, 2025 data cutoff, together with follow-up data from the 12 mg dose cohort, remained consistent with previously reported safety data. Pociredir was generally well-tolerated, with no treatment-related SAEs and no discontinuations due to treatment-related AEs as of the November 11, 2025, data cutoff. ASH Investor Event Information
Fulcrum Therapeutics, Inc. will host a live and webcast investor event featuring company leadership and medical experts on Sunday, December 7, 2025 at 7:00 a.m. ET in Orlando to discuss the results to date from the PIONEER Phase 1b trial. The event will be webcast live and can be accessed under “Events and Presentations” in the Investor Relations section of Fulcrum’s website (www.fulcrumtx.com), with a recording available following the event. Individuals may register to participate in the webcast using the conference link here.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

About Pociredir
Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment of SCD. Initial data in SCD in the PIONEER Phase 1b clinical trial showed proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. Through the completion of the 12 mg dose cohort, pociredir was demonstrated to be generally well-tolerated in people with SCD with up to three months of exposure, with no treatment-related serious adverse events reported. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. To learn more about clinical trials of pociredir please visit ClinicalTrials.gov.

About Sickle Cell Disease
SCD is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.

About PIONEER
PIONEER (NCT05169580) is a Phase 1b open-label dose-escalation clinical trial evaluating the safety and efficacy of pociredir, an oral once-daily HbF inducer, in adult patients with severe SCD. Secondary endpoints include HbF induction, hemolysis, and anemia. Exploratory endpoints include globin gene expression, % F-cells and incidence of VOCs. Fulcrum has previously completed cohort 1 (6 mg, n=10), cohort 2 (2 mg, n=2), cohort 3a (12 mg, n=4), and cohort 3b (12 mg, n=16). Initial results of cohort 4 (20 mg, n=12) are reported today. A total of 13 patients enrolled, but there was one discontinuation due to death, which was determined by the investigator to be unrelated to treatment following complications from VOC reported on Day 1 of the study. The pharmacodynamic (PD) analysis data for cohort 4 includes 12 patients, of which 50% (n=6) reached 12 weeks of the November 11, 2025 data cut, and 100% (n=12) reached at least 6 weeks as of the data cut. The safety analysis set for 20mg includes all 13 patients who enrolled.

Forward-Looking Statements 
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including express or implied statements regarding the significance of initial results from the 20 mg cohort; Fulcrum’s goals for pociredir; pociredir’s best-in-class potential for the treatment of SCD; pociredir’s ability to induce HbF, the durability or clinical relevance of early HbF and hemolysis improvements; and VOCs during the 12-week treatment period, among others. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, including express or implied statements regarding Fulcrum’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with completing the 20mg cohort in the PIONEER clinical trial; achieving the same results in the full cohort as observed in a limited number of patients after six weeks; Fulcrum’s ability to continue to advance pociredir and its other product candidates in clinical trials, including enrollment and completion; estimating the potential patient population and/or market for Fulcrum's product candidates; interpreting initial clinical data, including the risk that early data (such as week 6 data from the 20 mg cohort) may not be predictive of full cohort results, later timepoints, or future studies; replicating in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of pociredir and any other product candidates; obtaining, maintaining or protecting intellectual property rights related to its product candidates; managing expenses; and managing risks associated therewith; and raising the substantial additional capital needed to achieve its business objectives; among others. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Fulcrum’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in Fulcrum’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Fulcrum’s views as of the date hereof and should not be relied upon as representing Fulcrum’s views as of any date subsequent to the date hereof. Fulcrum anticipates that subsequent events and developments will cause Fulcrum’s views to change. However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Western Alliance Bancorporation (NYSE: WAL) resulting from allegations that Western Alliance Bancorporation may have issued materially misleading business information to the investing public.

So what: If you purchased Western Alliance Bancorporation securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46349 https://rosenlegal.com/submit-form/?case_id=39889 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On October 16, 2025, Western Alliance Bancorporation disclosed that it had initiated a lawsuit against a borrower, Cantor Group V LLC, alleging fraud related to collateral loans.

On this news, Western Alliance Bancorporation's stock fell 10.88% on October 16, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

December 06, 2025 5:35 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Skye class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Skye's business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Skye Bioscience class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277190

Make sure your portfolio is prepared for any kind of market with dividend stocks.

As 2025 comes to a close, the S&P 500 is up 16.6%, and there's real potential of a third year in a row of double-digit gains for the index. Does that spell trouble for 2026? Not necessarily. However, investors should be prepared at all times for the possibility of market volatility.

Part of that preparation is having a diversified portfolio of stocks, and that includes great dividend stocks. Dividend stocks are your anchors at any time, and they fortify your portfolio in case it needs to weather market turbulence. If you're looking to shore up your portfolio, Realty Income (O +0.37%) could be the best dividend stock to buy right now.

Image source: Getty Images.

Everything you need in a top dividend stock
Realty Income is a real estate investment trust (REIT). REITs own and lease properties, and they pay out 90% of their earnings as dividends, which is why they often feature in the dividend portion of a great portfolio.

There are different types of REITs depending on the industry, and Realty Income is a retail REIT. Its client list includes resilient essentials retailers that can perform well in any environment, like Walmart and CVS, and no client makes up more than 3.3% of the total property portfolio. Although 80% of its properties are in retail, it has expanded into other industries like gaming and industrials, and it's also spreading out globally. This lowers its overall risk.

Today's Change

(

0.37

%) $

0.21

Current Price

$

58.42

This stable model is how Realty Income can support an incredible and unusual dividend. It pays its dividend monthly and raises it quarterly. The company has paid it out without fail for the past 665 months, or more than 55 years, and raised it for 112 consecutive quarters.

Realty Income's dividend yields 5.5% at the current price, rounding out all the ways it provides value for passive income investors, and it could be the best dividend stock to buy right now.

Jennifer Saibil has positions in Walmart. The Motley Fool has positions in and recommends Realty Income and Walmart. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December 4, 2024 and September 9, 2025, both dates inclusive (the "Class Period"), of the important December 30, 2025 lead plaintiff deadline.

So What: If you purchased Synopsys securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Synopsys class action, go to https://rosenlegal.com/submit-form/?case_id=44981 https://rosenlegal.com/submit-form/?case_id=39889or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the Case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) the extent to which Synopsys' increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (2) that, as a result, "certain road map and resource decisions" were unlikely to "yield their intended results,"; (3) that the foregoing had a material negative impact on financial results; and (4) as  a result of the foregoing, defendants' positive statements about Synopsys' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Synopsys class action, go to https://rosenlegal.com/submit-form/?case_id=44981 https://rosenlegal.com/submit-form/?case_id=39889or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

The carrier won't have to pay $11 million related to its 2022 meltdown during the holiday season.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Klarna Group plc (NYSE: KLAR) resulting from allegations that Klarna may have issued materially misleading business information to the investing public. So What: If you purchased Klarna securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Ro.

HomeEarnings AnalysisConsumer Staples Analysis

SummaryCENT demonstrates operational excellence, with FY25 marking a pivotal margin expansion and a resilient operating base.It's multi-year Cost & Simplicity program, portfolio reshaping, and facility consolidation have structurally improved margins, outpacing industry peers.Despite weak consumer confidence and $20M in incremental tariffs, CENT maintains disciplined cost controls and targets continued profit expansion in FY26. Klaus Vedfelt/DigitalVision via Getty Images

Synopsis In my previous coverage, I highlighted (CENT)’s operational excellence as a result of its multi-year Cost & Simplicity program that focuses on improving operational efficiencies to offset external headwinds. CENT’s 4Q25 results reinforce

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Corporate Bitcoin holdings have been treated as a straightforward signal for years: a company buys BTC, investors read it as conviction, and the stock trades with a built-in Bitcoin premium. While this might sound like a very clear and simple trade, the balance sheets behind it are anything but.

While Terraform Labs founder Do Kwon is slated for sentencing later this week and the Terra Classic v2.18 upgrade heads down the runway, both luna classic (LUNC) and luna (LUNA) have been enjoying a sharp climb over the past two weeks.